Here's Why GlycoMimetics Could Become a Takeover Target
Updated results from a trial evaluating GMI-1271 in relapsed or refractory acute myeloid leukemia (AML) sent GlycoMimetics (NASDAQ: GLYC) shares soaring earlier this week, but more good news next year could send shares even higher next year.
The company plans to begin a phase 3 study of GMI-1271 by the middle of 2018, and in the second half of 2018, data is expected from a phase 3 study evaluating GlycoMimetics and Pfizer's (NYSE: PFE) sickle-cell disease drug, rivipansel.
The potential to improve AML treatment and improve the lives of sickle-cell disease patients could make this company an intriguing takeover target, so let's learn more about GlycoMimetics' story.
Source: Fool.com
Glycomimetics Inc. Stock
€0.37
-78.310%
Currently there is a rather positive sentiment for Glycomimetics Inc. with 5 Buy predictions and 0 Sell predictions.
Based on the current price of 0.37 € the target price of 7 € shows a potential of 1791.89% for Glycomimetics Inc. which would more than double the current price.
